Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 12/2012

Open Access 01-12-2012 | Review Article

Rediscovering Trazodone for the Treatment of Major Depressive Disorder

Authors: Andrea Fagiolini, Alessandro Comandini, Mario Catena Dell’Osso, Siegfried Kasper

Published in: CNS Drugs | Issue 12/2012

Login to get access

Abstract

Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). The drug is approved and marketed in several countries worldwide for the treatment of major depressive disorder (MDD) in adult patients. In clinical studies, trazodone has demonstrated comparable antidepressant activity to other drug classes, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline (norepinephrine) reuptake inhibitors (SNRIs). Moreover, the SARI action of trazodone may overcome the tolerability issues that are often associated with second-generation antidepressants such as SSRIs (i.e. insomnia, anxiety and sexual dysfunction). Recent focus has been placed on the development of a new prolonged-release once-a-day formulation of trazodone (TzCOAD), which may provide improved tolerability over the conventional immediate-release formulation of trazodone. Clinical studies have led to the recent approval in the USA of TzCOAD (as Oleptro™; Angelini Labopharm LLC, Princeton, NJ, USA), which may see resurgence of interest in the drug for the management of patients with MDD. Although trazodone is approved for the treatment of depression, evidence supports the use of low-dose trazodone as an off-label hypnotic for the treatment of sleep disorders in patients with MDD. The most common adverse effects reported with trazodone are drowsiness (somnolence/sedation), headache, dizziness and dry mouth. Other events reported, albeit with low incidence, include orthostatic hypotension (particularly in elderly patients or those with heart disease), minimal anticholinergic activity, corrected QT interval prolongation and torsade de pointes, cardiac arrhythmias, and rare occurrences of priapism and suicidal ideation. Overall, trazodone is an effective and well tolerated antidepressant (SARI) with an important role in the current treatment of MDD both as monotherapy and as part of a combination strategy. Trazodone is effective in controlling a wide range of symptoms of depression, while avoiding the negative effects on sleep seen with SSRI antidepressants. The recently approved prolonged-release formulation should provide further optimization of this antidepressant and may be useful for enabling an appropriate therapeutic dose to be administered with improved patient compliance.
Literature
1.
2.
Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(Suppl E1):e08.
3.
Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859–77.CrossRefPubMed
4.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington: American Psychiatric Association; 2010.
5.
Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67–104.CrossRefPubMed
6.
Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.
7.
Harter M, Klesse C, Bermejo I, et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int. 2010;107(40):700–8.PubMed
8.
9.
Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(Suppl 13):18–25.PubMed
10.
Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010;71(8):971–5.CrossRefPubMed
11.
Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22(9):1825–37.CrossRefPubMed
12.
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.CrossRefPubMed
13.
Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221–5.CrossRefPubMed
14.
Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–66.CrossRefPubMed
15.
Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37–41.PubMed
16.
Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(Suppl 16):27–32.PubMed
17.
Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002;22(2):137–47.CrossRefPubMed
18.
Thase ME. Treatment issues related to sleep and depression. J Clin Psychiatry. 2000;61(Suppl 11):46–50.PubMed
19.
Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology. 1988;95(Suppl):S50–3.PubMed
20.
Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734–50.CrossRefPubMed
21.
Extended-release trazodone (Oleptro) for depression. Med Lett Drugs Ther. 2010;52(1351):91–2.
22.
Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536–46.PubMed
23.
Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981;21(6):401–29.CrossRefPubMed
24.
Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005;19(3):235–41.CrossRefPubMed
25.
Stahl SM. Stahl’s essential psychopharmacology. 3rd ed. New York (NY): Cambridge University Press; 2008.
26.
Marek GJ, Carpenter LL, McDougle CJ, Price LH. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003;28(2):402–12.CrossRefPubMed
27.
Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53(3):83–5.PubMed
28.
Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999;383(3):249–57.CrossRefPubMed
29.
Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24(12):726–31.CrossRefPubMed
30.
Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13(12):1027–38.PubMed
31.
32.
33.
Oleptro™ (trazodone hydrochloride) extended-release tablets. P T 2011;36(2):2–18.
34.
Rawls WN. Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). Drug Intell Clin Pharm. 1982;16(1):7–13.PubMed
35.
Karhu D, Gossen ER, Mostert A, et al. Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects. Int J Clin Pharm Ther. 2011;49(12):730–43.
36.
Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22(7):444–7.CrossRefPubMed
37.
Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294–9.PubMed
38.
Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99–106.CrossRefPubMed
39.
Kasper S, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21(8):1139–46.CrossRefPubMed
40.
Moon CA, Laws D, Stott PC, Hayes G. Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice. Curr Med Res Opin. 1990;12(3):160–8.CrossRefPubMed
41.
Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22(9):1703–13.CrossRefPubMed
42.
Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry. 2009;6(5):20–33.PubMed
43.
Sheehan DV, Rozova A, Gossen ER, Gibertini M. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull. 2009;42(4):5–22.PubMed
44.
van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995;10(1):3–9.CrossRefPubMed
45.
Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14(3):170–9.CrossRefPubMed
46.
Blacker R, Shanks NJ, Chapman N, Davey A. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology. 1988;95(Suppl):S18–24.PubMed
47.
Botros WA, Ankier SI, Priest RG, et al. Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone. Br J Psychiatry. 1989;155:479–82.CrossRefPubMed
48.
Davey A. A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology. 1988;95(Suppl):S25–30.PubMed
49.
Debus JR, Rush AJ, Himmel C, et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry. 1988;49(11):422–6.PubMed
50.
Moon CA, Davey A. The efficacy and residual effects of trazodone (150 mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology. 1988;95(Suppl):S7–13.PubMed
51.
Altamura AC, Mauri MC, Rudas N, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol. 1989;12(Suppl 1):S25–33 (S4–7).
52.
Ather SA, Ankier SI, Middleton RS. A double-blind evaluation of trazodone in the treatment of depression in the elderly. Br J Clin Pract. 1985;39(5):192–9.PubMed
53.
Gerner R, Estabrook W, Steuer J, Jarvik L. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980;41(6):216–20.PubMed
54.
Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol. 1989;2(4):208–14.CrossRefPubMed
55.
Bayer AJ, Pathy MS, Cameron A, et al. A comparative study of conventional and controlled-release formulations of trazodone in elderly depressed patients. Clin Neuropharmacol. 1989;12(Suppl 1):S50–5 (discussion S6–7).
56.
Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders: American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1998;37(11):1234–8.CrossRefPubMed
57.
Saccomani L, Rizzo P, Nobili L. Combined treatment with haloperidol and trazodone in patients with tic disorders. J Child Adolesc Psychopharmacol. 2000;10(4):307–10.CrossRefPubMed
58.
Catanese B, Dionisio A, Barillari G, De Martino C. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function. Boll Chim Farm. 1978;117(7):424–7.PubMed
59.
Detry O, Delwaide J, De Roover A, et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. Transplant Proc. 2009;41(8):3435–6.CrossRefPubMed
60.
Agnoli A, De Gregorio M, Dionisio A. Trazodone, a review of clinical literature and personal experience. Psychopathology. 1984;17(Suppl 2):88–103.CrossRefPubMed
61.
Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331–55.CrossRefPubMed
62.
Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol. 1982;23(5):417–21.CrossRefPubMed
63.
Glassman AH. The newer antidepressant drugs and their cardiovascular effects. Psychopharmacol Bull. 1984;20(2):272–9.PubMed
64.
de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258–61.PubMed
65.
Aronson MD, Hafez H. A case of trazodone-induced ventricular tachycardia. J Clin Psychiatry. 1986;47(7):388–9.PubMed
66.
Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest. 1990;98(1):247–8.CrossRefPubMed
67.
Winkler D, Ortner R, Pjrek E, et al. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol. 2006;21(1):61–2.CrossRefPubMed
68.
Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469–76.CrossRefPubMed
69.
Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol. 2005;510(1–2):75–85.CrossRefPubMed
70.
Jayaram G, Rao P. Safety of trazodone as a sleep agent for inpatients. Psychosomatics. 2005;46(4):367–9.CrossRefPubMed
71.
Stryjer R, Strous RD, Bar F, et al. Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone. Clin Neuropharmacol. 2003;26(3):137–41.CrossRefPubMed
72.
Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990;51(10):430–3.PubMed
73.
Prapotnik M, Waschgler R, Konig P, et al. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharm Ther. 2004;42(2):120–4.
74.
Bertschy G, Ragama-Pardos E, Muscionico M, et al. Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. Pharmacol Res. 2005;51(1):79–84.CrossRefPubMed
75.
Fabre LF Jr, Feighner JP. Long-term therapy for depression with trazodone. J Clin Psychiatry. 1983;44(1):17–21.PubMed
76.
Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13(12):1707–17.
77.
Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000;23(Suppl 1):S23–30 (discussion S6–8).
78.
Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):249–60.CrossRefPubMed
79.
Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiol. 2001;44(3):139–49.CrossRef
80.
Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49–56.CrossRefPubMed
81.
Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16(2):139–44.CrossRefPubMed
82.
Wheatley D. Trazodone: alternative dose regimens and sleep. Pharmatherapeutica. 1984;3(9):607–12.PubMed
83.
Walsh JB, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191–8.CrossRef
84.
Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069–72.PubMed
85.
Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51(Suppl):13–7.PubMed
86.
Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(Suppl)17:28–31 (discussion 46–8).
87.
Kallepalli BR, Bhatara VS, Fogas BS, et al. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adolesc Psychopharmacol. 1997;7(2):97–107.CrossRefPubMed
88.
Haffmans PM, Vos MS. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry. 1999;14(3):167–71.CrossRefPubMed
89.
Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology. 1999;144(3):220–33.CrossRefPubMed
90.
Rush CR, Madakasira S, Hayes CA, et al. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. Psychopharmacology. 1997;131(1):9–18.CrossRefPubMed
91.
Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990;15(2):123–35.CrossRefPubMed
92.
Wittchen HU, Lieb R, Wunderlich U, Schuster P. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry. 1999;60(Suppl 7):29–36 (discussion 7–8).
93.
Gale CK. The treatment of generalised anxiety disorder: a systematic review. Panminerva Med. 2002;44(4):283–6.PubMed
94.
Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884–95.CrossRefPubMed
95.
Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996;16(4):294–8.CrossRefPubMed
96.
Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128–31.CrossRefPubMed
97.
Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987;144(6):785–7.PubMed
98.
Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986;47(12):580–6.PubMed
99.
Milton S, Hershey Medical Center. Efficacy of trazodone vs. cognitive behavioral therapy in patients with chronic insomnia associated with objective short sleep duration [ClinicalTrials.gov identifier NCT01348542]. US National Institutes of Health, ClinicalTrials.gov. http://​www.​clinicaltrials.​gov. Accessed 5 June 2012.
100.
Zavesicka L, Brunovsky M, Horacek J, et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett. 2008;29(6):895–901.PubMed
101.
Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004;5(1):15–20.CrossRefPubMed
102.
Yamadera H, Suzuki H, Nakamura S, Endo S. Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers. Psychiatry Clin Neurosci. 1999;53(2):189–91.CrossRefPubMed
103.
Mouret J, Lemoine P, Minuit MP, et al. Effects of trazodone on the sleep of depressed subjects: a polygraphic study. Psychopharmacology. 1988;95(Suppl):S37–43.PubMed
104.
Parrino L, Spaggiari MC, Boselli M, et al. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology. 1994;116(4):389–95.CrossRefPubMed
105.
van Bemmel AL, Havermans RG, van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology. 1992;107(4):569–74.CrossRefPubMed
106.
Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry. 1990;51(Suppl):18–22.PubMed
107.
Metadata
Title
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Authors
Andrea Fagiolini
Alessandro Comandini
Mario Catena Dell’Osso
Siegfried Kasper
Publication date
01-12-2012
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 12/2012
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-012-0010-5

Other articles of this Issue 12/2012

CNS Drugs 12/2012 Go to the issue

Adis Drug Profile

Perampanel

Commentary

New Hope for Survivors of Stroke and Traumatic Brain Injury

Leading Article

Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

Adis Drug Profile

Gabapentin Enacarbil

Original Research Article

Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury

Acknowledgement

Acknowledgments